Futuremeds S.R.L.
- Address
- Aleea Meteo 4, 800183 Galati, Romania
Dermatology and Immune System Diseases
At Futuremeds S.R.L. in Galati, research in dermatology focuses on atopic dermatitis and moderate-to-severe hidradenitis suppurativa. These studies are designed to evaluate how well new treatments control inflammation, improve symptoms, and help people who have not responded adequately to current care.
- Testing a new treatment option for atopic dermatitis when standard therapy has not worked well enough
- Assessing whether a therapy for hidradenitis suppurativa can better reduce disease burden than placebo
The site’s work in this area highlights efforts to improve treatment effectiveness for chronic, difficult-to-manage skin conditions.
Nutritional and Metabolic Diseases
Clinical research in nutritional and metabolic diseases at this Romanian site centers on obesity and type 2 diabetes. The trials are aimed at understanding whether new therapies can support meaningful weight reduction and improve metabolic health in adults.
- Evaluating a once-weekly treatment for obesity and overweight
- Studying whether the same approach may also benefit people living with type 2 diabetes
These studies reflect a strong interest in therapies that may help address long-term weight-related and metabolic conditions.
Cancer-associated Cachexia Research
The site also participates in studies on cancer-associated cachexia, a serious condition linked to cancer-related weight loss and muscle wasting. This area of research is focused on testing whether investigational therapies can help preserve body mass, improve strength, and support overall well-being.
- Investigating a potential therapy for cachexia in people with cancer
- Exploring treatment options intended to improve nutritional and physical outcomes
At Futuremeds S.R.L., this work adds an important supportive-care dimension to the broader clinical trial portfolio.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Futuremeds S.R.L.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of Upadacitinib for the Treatment of Adult Subjects with Moderate to Severe Atopic Dermatitis and Inadequate Response to Dupilumab (SWITCH-UP) | AbbVie Deutschland GmbH & Co. KG | Phase I | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dupilumab | 1 | Unknown | 2026-03-05 | 2026-03-05 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.